Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D43GZX
|
|||
| Drug Name |
SAR566658
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 2 | [1] | |
| Company |
Sanofi
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carbonic anhydrase VI (CA-VI) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Nitrogen metabolism | |||
| Reactome | Reversible hydration of carbon dioxide | |||
| WikiPathways | Reversible Hydration of Carbon Dioxide | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02984683) Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer. U.S. National Institutes of Health. | |||
| REF 2 | An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. Mol Cancer Ther. 2020 Aug;19(8):1660-1669. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.